Dr. John Leonard is the president and CEO of Intellia Therapeutics. After a 30–year career in pharmaceutical research and development (R&D), Dr. Leonard retired from his position as chief scientific officer and senior vice president of R&D at AbbVie in 2013. Inspired by the opportunity to work with a new therapeutic modality and form a new company, he returned to his life’s passion and joined the Intellia team to direct the research and development effort to make CRISPR/Cas9 technology into a therapeutic reality.
Prior to becoming Intellia’s CEO, John was among the leading R&D executives who led breakthrough medicines through their discovery, development and launch of blockbuster drugs. While serving as the global head of pharmaceutical R&D at Abbott Laboratories, John oversaw the development of numerous novel therapeutics. His ground–breaking work with HIV protease inhibitors Norvir® and Kaletra® led to new treatment paradigms for AIDS, his years of work with Humira® made it the all–time top–selling drug worldwide, and he led significant growth of the R&D pipeline at Abbott and Abbvie. John’s teams were twice recognized with the prestigious Prix Galien Award for excellence in pharmaceutical research.
In addition to serving on the board of directors of Intellia, John serves on the board of directors of QuintilesIMS (NYSE:Q) and Chimerix (NASDAQ:CMRX). He received his M.D. from the Johns Hopkins University School of Medicine and completed his residency in internal medicine at Stanford University School of Medicine followed by a fellowship at the U.S. National Institutes of Health.
Dr. John Leonard is the president and CEO of Intellia Therapeutics. After a 30-year career in pharmaceutical R&D, Dr. Leonard retired from his position as chief scientific officer and senior vice president of research and development at AbbVie in 2013. Inspired by the opportunity to work with a new therapeutic modality and form a new company, he returned to his life’s passion and joined the Intellia team to direct the research and development effort to make CRISPR/Cas9 technology into a therapeutic reality.
Prior to becoming Intellia’s CEO, John was among the leading R&D executives who led breakthrough medicines through their discovery, development and launch of blockbuster drugs. While serving as the global head of pharmaceutical R&D at Abbott Laboratories, John oversaw the development of numerous novel therapeutics. His ground-breaking work with HIV protease inhibitors Norvir® and Kaletra® led to new treatment paradigms for AIDS, his years of work with Humira® made it the all-time top-selling drug worldwide, and he led significant growth of the R&D pipeline at Abbott and Abbvie. John’s teams were twice recognized with the prestigious Prix Galien Award for excellence in pharmaceutical research.
In addition to serving on the board of directors of Intellia, John serves on the board of directors of QuintilesIMS (NYSE:Q) and Chimerix (NASDAQ:CMRX). He received his M.D. from the Johns Hopkins University School of Medicine and completed his residency in internal medicine at Stanford University School of Medicine followed by a fellowship at the U.S. National Institutes of Health.